Key points are not available for this paper at this time.
ABSTRACT Atopic dermatitis (AD), a chronic inflammatory, pruritic skin disorder, is seen primarily in the pediatric population but can be found among all age groups. The symptoms of AD can cause embarrassment in patients and can interrupt daily activities and productivity, potentially resulting in avoidance of social situations. In addition to nonpharmacologic management, mainstay pharmacologic treatments for AD are topical medications including corticosteroids, calcineurin inhibitors, phosphodiesterase-4 inhibitors, and topical Janus kinase (JAK) inhibitors. Promising new drugs—oral JAK inhibitors and monoclonal antibodies—have emerged as new treatment options for moderate-to-severe AD.
Lynda Jarrell (Thu,) studied this question.